Mresvia (Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In)

The active ingredient is a single‑stranded 5' capped mRNA that encodes the RSV F glycoprotein. After intramuscular injection, host cells translate the mRNA into the F protein, which is then recognized by the immune system, prompting the production of neutralizing antibodies and cellular immunity that protect against future RSV exposure.

The dosage and administration schedule for Mresvia are determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunization guidelines. The prescriber will set the appropriate dose and timing for each individual.

Safety data for Mresvia in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risks and benefits with patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Mresiva uses an mRNA platform to express the RSV F glycoprotein, whereas many existing RSV vaccines are based on recombinant protein or live‑attenuated virus technologies. The mRNA approach can offer rapid manufacturing and potentially broader immune responses, but comparative efficacy and safety are evaluated in clinical studies specific to each product.

Mresvia must be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Mresvia is given by intramuscular injection, typically into the deltoid muscle. The injection should be performed by a qualified healthcare professional following aseptic technique and according to the prescribed dosing schedule.

Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, myocarditis, severe allergic reactions, seizures, and thrombotic events. Patients should be observed after vaccination and seek immediate medical care if any severe symptoms develop.

Mresvia should not be administered to individuals with a known severe allergy to any component of the vaccine. It is also contraindicated in persons who have experienced a previous severe reaction to an RSV vaccine. Clinical judgment is required for patients with compromised immune systems or other special conditions.